Early effects of human papillomavirus vaccination in Belgium


A study on the early effects of human papillomavirus vaccination in Belgium.
Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12–15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 and a non-significant reduction in HPV 18 was found in the youngest group (15–19 years). The prevalence in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.

Authors & affiliation: 
Mireille Merckxa,b,*, Davy Vanden Broecka,*, Ina Benoyc, Christophe Depuydtc,Steven Weyersb and Marc Arbynd aInternational Centre for Reproductive Health (ICRH), Ghent University, bDepartment of Obstetrics and Gynaecology, Ghent University Hospital, Ghent, cSonic Health Care/AML, Antwerp and dUnit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
Staff Members: 
Published In: 
Eur J Cancer Prev. 2014 Aug 11
Publication date: 
Monday, August 11, 2014